Moreover, TAP-positive incidence was found to be more frequent than AFP and CA19-9 in liver and pancreatic cancer, respectively (Tables 5 and 6), suggesting the advantage of TAP over these established markers. The gene discussed is AFP; the disease is familial pancreatic carcinoma.